Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis

Documenti analoghi

• Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction
  di: Esraa Eloseily, et al.
  Pubblicazione: (2024)
• Physician‐Scientist Pipeline for Pediatric Rheumatology: The Current Landscape and Future Perspectives
  di: Ekemini A. Ogbu, et al.
  Pubblicazione: (2026)
• Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial
  di: Hermine I. Brunner, et al.
  Pubblicazione: (2025)
• 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges
  di: Michael Shishov, et al.
  Pubblicazione: (2025)
• IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura
  di: Ilia Spivak, et al.
  Pubblicazione: (2025)